Clinical trials: Multiple Sclerosis (MS) - Relapsing-remitting
- Condition Multiple Sclerosis (MS) - Relapsing-remitting
- Funder type Industry (pharma, biotech, devices)
Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"
This protocol is part of a clinical study to evaluate efficacy and safety of multiple intravenous administrations of HB-adMSCs for the treatment of Multiple Sclerosis.
- Trial name
- MS (NCT06800404)
- Testing
- Autologous HB-adMSCs
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hope Biosciences Research Foundation
Multiple Sclerosis
Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.
The purpose of this study is to investigate the clinical status of patients who participated in the original pivotal Betaseron study at 20 years after randomized treatment initiationStudy end-points include: 1.
- Trial name
- NCT01031459
- Testing
- Betaseron (Interferon beta-1b, BAY86-5046)
- Where
- 10 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing-Remitting
A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)
The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus…
- Trial name
- INCREASE (NCT03387046)
- Testing
- D-aspartate, IFN beta-1a, Methylprednisolone
- Where
- 17 sites in Italy
- Volunteers
- 7 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFNß) or glatiramer acetate (GA) in participants with relapsing-remitting…
- Trial name
- EXPLORE (NCT01156311)
- Testing
- dimethyl fumarate
- Where
- 16 sites in United States
- Volunteers
- 108 people
- Sponsor
- Biogen
Relapse Remitting Multiple Sclerosis
Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline
This study investigates the add-on effect of oral minocycline in subjects treated with daily injection of Copaxone. Copaxone and minocycline are thought to have differential modes of actions that may complement each other in…
- Trial name
- NCT00203112
- Testing
- glatiramer acetate with minocycline
- Volunteers
- 44 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Remitting Multiple Sclerosis (RRMS)
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
This study evaluated disease control during different lengths of treatment transition from natalizumab to fingolimod.
- Trial name
- TOFIINGO (NCT01499667)
- Testing
- Fingolimod
- Where
- 44 sites in Australia, Austria and 9 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching…
- Trial name
- SONATA-MS (NCT07827586)
- Testing
- Ocrelizumab
- Where
- Slovenia
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Relapsing-Remitting Multiple Sclerosis
An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone
This was an open-label, multicentric, prospective, post-marketing surveillance (PMS) study to investigate whether baseline treatment with high-dose interferon beta 1a (Rebif 44 μg x 3 ), administered at a high frequency, leads to…
- Trial name
- RETURN (NCT01142518)
- Testing
- Interferon beta 1a
- Volunteers
- 86 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-remitting Multiple Sclerosis
Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS
The primary objective of this study is to determine whether combination treatment (adding methylprednisolone to Avonex) reduces progression of disability over 4 years compared to Avonex alone.
- Trial name
- NCT00168766
- Testing
- Interferon-beta-1a (Avonex) plus methylprednisolone
- Where
- 9 sites in Belgium, Denmark and 6 more
- Volunteers
- 345 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
The purpose of this study is to determine if natalizumab in combination with Glatiramer Acetate (GA) is safe and effective in delaying progression of individuals diagnosed with relapsing-remitting Multiple Sclerosis (MS).
- Trial name
- NCT00097760
- Testing
- Natalizumab
- Volunteers
- 110 people
- Sponsor
- Biogen
Multiple Sclerosis
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events
- Trial name
- NCT02232061
- Testing
- Fingolimod
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
The primary objective of the study is to estimate the annualized relapse rate (ARR) in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who are treated with dimethyl fumarate (DMF) over a 12-month period.
- Trial name
- PROTEC (NCT01930708)
- Testing
- dimethyl fumarate
- Where
- 90 sites in Austria, Belgium and 9 more
- Volunteers
- 1,114 people
- Sponsor
- Biogen